CD274 and esophageal squamous cell carcinoma: Additionally, pembrolizumab–chemotherapy continued to provide durable responses, with ≥ 26.7% of all randomly assigned patients and patients with ESCC, PD-L1 CPS ≥ 10, and ESCC PD-L1 CPS ≥ 10 continuing to respond for ≥ 24 months per Kaplan–Meier estimates.